Jefferies Financial Group Inc. Takes Position in Bio-Rad Laboratories, Inc. $BIO

Jefferies Financial Group Inc. acquired a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 3,300 shares of the medical research company’s stock, valued at approximately $796,000.

A number of other institutional investors have also recently bought and sold shares of the company. Y Intercept Hong Kong Ltd purchased a new stake in shares of Bio-Rad Laboratories during the 1st quarter worth about $206,000. Avantax Advisory Services Inc. raised its position in Bio-Rad Laboratories by 26.5% during the first quarter. Avantax Advisory Services Inc. now owns 5,487 shares of the medical research company’s stock valued at $1,336,000 after acquiring an additional 1,151 shares in the last quarter. Cetera Investment Advisers raised its position in Bio-Rad Laboratories by 12.5% during the first quarter. Cetera Investment Advisers now owns 1,932 shares of the medical research company’s stock valued at $471,000 after acquiring an additional 215 shares in the last quarter. Assetmark Inc. lifted its stake in Bio-Rad Laboratories by 15.7% in the first quarter. Assetmark Inc. now owns 9,152 shares of the medical research company’s stock valued at $2,229,000 after acquiring an additional 1,242 shares during the last quarter. Finally, TD Asset Management Inc grew its position in Bio-Rad Laboratories by 11.2% in the first quarter. TD Asset Management Inc now owns 1,811 shares of the medical research company’s stock worth $441,000 after acquiring an additional 182 shares in the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on BIO shares. Weiss Ratings restated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Tuesday. Citigroup increased their target price on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Wells Fargo & Company raised their target price on Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Zacks Research upgraded Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Finally, Wall Street Zen lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, November 22nd. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of “Hold” and a consensus price target of $358.50.

Bio-Rad Laboratories Stock Down 1.6%

Bio-Rad Laboratories stock opened at $326.95 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.12 and a quick ratio of 3.67. Bio-Rad Laboratories, Inc. has a fifty-two week low of $211.43 and a fifty-two week high of $373.69. The firm has a fifty day moving average price of $308.31 and a two-hundred day moving average price of $274.75. The firm has a market cap of $8.82 billion, a price-to-earnings ratio of -13.45 and a beta of 1.04.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Wednesday, October 29th. The medical research company reported $2.26 EPS for the quarter, missing analysts’ consensus estimates of $2.30 by ($0.04). Bio-Rad Laboratories had a positive return on equity of 4.18% and a negative net margin of 26.43%.The business had revenue of $653.00 million during the quarter, compared to the consensus estimate of $651.30 million. During the same quarter in the previous year, the firm posted $2.01 earnings per share. The company’s revenue for the quarter was up .5% on a year-over-year basis. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. As a group, analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Insider Buying and Selling

In other Bio-Rad Laboratories news, EVP James Barry sold 700 shares of Bio-Rad Laboratories stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $306.18, for a total value of $214,326.00. Following the transaction, the executive vice president directly owned 510 shares of the company’s stock, valued at $156,151.80. The trade was a 57.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 17.83% of the stock is currently owned by corporate insiders.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.